Evidence map›Paper›PMID 39212656›Full record

ArticleThe Journal of experimental medicine2024

RAC2 gain-of-function variants causing inborn error of immunity drive NLRP3 inflammasome activation.

Anne Doye, Paul Chaintreuil, Chantal Lagresle-Peyrou, Ludovic Batistic, Valentine Marion, Patrick Munro, Celine Loubatier, Rayana Chirara, Nataël Sorel, Boris Bessot and 16 more

Registry-linked trialAbstract read
In one paragraph

Article in The Journal of experimental medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03869593 (Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus Bacteria), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03869593 terminatednot on this map

Role of the NLRP3 Inflammasome in Escherichia Coli and Staphylococcus Aureus Bacteria

TypeobservationalSponsorCentre Hospitalier Universitaire de NiceRan2019 to 2023Enrolled60ConditionsEscherichia Coli Infections, Staphylococcus AureusArmsSample analysis
3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. How Functional Variants Reconfigure the Rac2 Conformational Landscape.bioRxiv : the preprint server for biology · 2026
    Article
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Anne Doye *Université Côte d'Azur, INSERM, C3M , Nice, France.ORCID 0000-0001-6466-9326
Paul Chaintreuil *Université Côte d'Azur, INSERM, C3M , Nice, France.ORCID 0000-0002-4845-7304
Chantal Lagresle-Peyrou *Université Paris Cité , Paris, France.ORCID 0000-0002-2216-6453
Ludovic BatisticUniversité Côte d'Azur, INSERM, C3M , Nice, France.ORCID 0000-0002-3732-0783
Valentine MarionUniversité Côte d'Azur, INSERM, C3M , Nice, France.ORCID 0000-0002-3215-6590
Patrick MunroUniversité Côte d'Azur, INSERM, C3M , Nice, France.ORCID 0000-0003-4283-4671
Celine LoubatierUniversité Côte d'Azur, INSERM, C3M , Nice, France.ORCID 0000-0001-5727-342X
Rayana ChiraraUniversité Côte d'Azur, INSERM, C3M , Nice, France.ORCID 0000-0001-8642-192X
Nataël SorelImagine Institute, INSERM UMR 1163 , Paris, France.ORCID 0009-0000-8202-0600
Boris BessotImagine Institute, INSERM UMR 1163 , Paris, France.ORCID 0009-0008-8969-7284
Pauline BronnecCentre International de Recherche en Infectiologie, Université de Lyon, Inserm U1111 , Lyon, France.ORCID 0009-0002-1942-7621
Julie ContentiUniversité Côte d'Azur, INSERM, C3M , Nice, France.ORCID 0000-0002-1532-6180
Johan CourjonUniversité Côte d'Azur, INSERM, C3M , Nice, France.ORCID 0000-0002-0445-5104
Valerie GiordanengoUniversité Côte d'Azur, INSERM, C3M , Nice, France.ORCID 0000-0002-5114-1124
Arnaud JacquelUniversité Côte d'Azur, INSERM, C3M , Nice, France.ORCID 0000-0001-5062-8048
Pascal BarbryUniversité Côte d'Azur, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire , Sophia-Antipolis, France.ORCID 0000-0001-9632-6483
Marie CouraletUniversité Côte d'Azur, CNRS, Institut de Pharmacologie Moléculaire et Cellulaire , Sophia-Antipolis, France.ORCID 0000-0002-4581-8418
Nathalie AladjidiCentre de Référence National des Cytopénies Autoimmunes de l'Enfant, Pediatric Hematologic Unit, Centre d'Investigation Clinique Plurithématique INSERM 1401, University Hospital of Bordeaux , Bordeaux, France.ORCID 0000-0003-0231-4460
Alain FischerImagine Institute, INSERM UMR 1163 , Paris, France.ORCID 0000-0003-4025-5983
Marina CavazzanaUniversité Paris Cité , Paris, France.ORCID 0000-0002-0264-0891
Coralie MallebrancheUniversité d'Angers, Université de Nantes, Inserm, CNRS, CRCI2NA, SFR ICAT , Angers, France.ORCID 0000-0002-8385-4057
Orane VisvikisUniversité Côte d'Azur, INSERM, C3M , Nice, France.ORCID 0000-0001-7719-5836
Sven KrackerUniversité Paris Cité , Paris, France.ORCID 0000-0003-4543-8236
Despina MoshousLaboratoire Dynamique du Génome et Système Immunitaire, Imagine Institute, INSERM UMR 1163 , Paris, France.ORCID 0000-0001-6719-3693
Els VerhoeyenUniversité Côte d'Azur, INSERM, C3M , Nice, France.ORCID 0000-0001-9224-5491
Laurent BoyerUniversité Côte d'Azur, INSERM, C3M , Nice, France.ORCID 0000-0002-1375-1706

Funding

Agence Nationale de la Recherche ANR-17-CE15-0001Association pour la Recherche sur le Cancer RAC15014AAACanceropôle PACAE-Rare Joint Transnational Call for Proposals 2015 EuroCIDFondation pour la Recherche Médicale EQU202403018053France Génomique National InfrastructureUniversité Côte d'Azur
6 · The paper itself

Abstract

A growing number of patients presenting severe combined immunodeficiencies attributed to monoallelic RAC2 variants have been identified. The expression of the RHO GTPase RAC2 is restricted to the hematopoietic lineage. RAC2 variants have been described to cause immunodeficiencies associated with high frequency of infection, leukopenia, and autoinflammatory features. Here, we show that specific RAC2 activating mutations induce the NLRP3 inflammasome activation leading to the secretion of IL-1β and IL-18 from macrophages. This activation depends on the activation state of the RAC2 variant and is mediated by the downstream kinase PAK1. Inhibiting the RAC2-PAK1-NLRP3 inflammasome pathway might be considered as a potential treatment for these patients.

Indexed as

Gain of Function MutationInflammasomesInterleukin-1betaMacrophagesNLR Family, Pyrin Domain-Containing 3 Proteinp21-Activated KinasesRAC2 GTP-Binding Proteinrac GTP-Binding ProteinsAnimalsHumansInterleukin-18MiceSignal TransductionInflammasomesInterleukin-18Interleukin-1betaNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanp21-Activated KinasesPAK1 protein, humanRAC2 GTP-Binding Proteinrac GTP-Binding Proteins

Identifiers

PMID39212656
PMCPMC11363864

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.